临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 学习指南:用主动回忆闪卡攻克核心考点
涵盖基础、中级和高级 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 闪卡卡组与8周复习路线图的完整学习指南(flashcards.world)。
Interactive Premade Curricula
Top 200 Prescribed Drugs (Brand, Generic, Class & MOA) Flashcard Decks (6)
Select any deck below to study cards with active recall, audio pronunciation, and FSRS spaced repetition, or filter by difficulty level.
Top 200 Drugs: Cardiovascular, Renal & Lipid-Lowering Agents (Brand, Generic, Class & MOA)
Top 200 Drugs: Antimicrobials (Antibiotics, Antivirals, Antifungals & Antimycobacterials)
Top 200 Drugs: Central Nervous System, Psychopharmacology & Analgesic Medications
Top 200 Drugs: Endocrine, Diabetes, Metabolic, Bone, Urologic & Gastrointestinal Pharmacology
Respiratory, Autonomic, Hematology & Oncology Pharmacology
在 flashcards.world 上浏览全部 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 闪卡卡组
1. 为什么主动回忆与间隔重复对 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 高效奏效
精通**临床最常处方 200 种核心药物(通用名、药理分类与作用机制)不仅需要深刻的概念理解,还需要快速、准确地提取核心术语、机制、规则和分析框架。无论你是在备战大学考试、职业资格认证还是实际应用,将主动回忆(Active Recall,看答案前先自测)与间隔重复(Spaced Repetition)相结合,都能有效打破“一看就会、一考就废”的错觉,将复杂的临床最常处方 200 种核心药物(通用名、药理分类与作用机制)**知识牢固写入长期记忆。
下方为你整理了结构化的学习路线图,直接链接至 flashcards.world 上按基础、中级、高级三个梯度精选的**临床最常处方 200 种核心药物(通用名、药理分类与作用机制)**闪卡卡组。
2. flashcards.world 精选 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 闪卡卡组(按难度分级)
基础阶段(A1–A2)
- Top 200 Drugs: Cardiovascular, Renal & Lipid-Lowering Agents (Brand, Generic, Class & MOA) (
en → en) — 在 flashcards.world 上学习此卡组 | 搜索basic - Top 200 Drugs: Antimicrobials (Antibiotics, Antivirals, Antifungals & Antimycobacterials) (
en → en) — 在 flashcards.world 上学习此卡组 | 搜索basic
中级阶段(B1–B2)
- Top 200 Drugs: Central Nervous System, Psychopharmacology & Analgesic Medications (
en → en) — 在 flashcards.world 上学习此卡组 | 搜索intermediate - Top 200 Drugs: Endocrine, Diabetes, Metabolic, Bone, Urologic & Gastrointestinal Pharmacology (
en → en) — 在 flashcards.world 上学习此卡组 | 搜索intermediate
高级阶段(C1–C2)
- Respiratory, Autonomic, Hematology & Oncology Pharmacology (
en → en) — 在 flashcards.world 上学习此卡组 | 搜索advanced - Pharmacokinetics, CYP450 Drug Interactions, TDM & Toxicology Antidotes (
en → en) — 在 flashcards.world 上学习此卡组 | 搜索advanced
3. 高频核心闪卡示例预览(临床最常处方 200 种核心药物(通用名、药理分类与作用机制))
| 难度 | 正面(问题 / 术语) | 背面(答案 / 解析) |
|---|---|---|
basic |
What are the pharmacological class, mechanism of action, and classic adverse effects of Lisinopril and Enalapril? | Class: ACE Inhibitors. MOA: Inhibit angiotensin-converting enzyme, decreasing Angiotensin II and aldosterone while increasing bradykinin. Adverse effects: Dry cough, angioedema, hyperkalemia, teratogenicity, acute creatinine rise in bilateral renal artery stenosis. |
basic |
What is the mechanism of action of Losartan and Valsartan, and what is their key clinical advantage over ACE inhibitors? | Class: Angiotensin II Receptor Blockers (ARBs). MOA: Selectively block AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone secretion. Advantage: Because ARBs do not inhibit ACE (kininase II), they do not impair bradykinin degradation and have a much lower incidence of dry cough and angioedema (though rare angioedema can still occur, so caution is warranted in patients with prior ACE-inhibitor angioedema). |
basic |
What are the mechanism of action and primary bacterial resistance mechanisms for Penicillin G and Amoxicillin? | Bind penicillin-binding proteins (PBPs/transpeptidases) to block peptidoglycan cross-linking in the bacterial cell wall, activating autolysins. Resistance occurs via beta-lactamase cleavage of the beta-lactam ring (overcome by adding clavulanate, sulbactam, or tazobactam) or altered PBPs (e.g., mecA/PBP2a in MRSA). |
basic |
What are the spectrum of activity and primary excretion pathway of the antistaphylococcal penicillins Nafcillin, Oxacillin, and Dicloxacillin? | Antistaphylococcal penicillins with bulky R-side chains that sterically block staphylococcal beta-lactamase. Active against MSSA and streptococci (no Gram-negative activity). Cleared predominantly via the biliary tract (no renal dose adjustment required). |
intermediate |
What are the mechanism of action, therapeutic lag mechanism, and classic adverse effects of the SSRIs Sertraline, Escitalopram, and Fluoxetine? | Selectively inhibit presynaptic serotonin transporter (SERT), increasing synaptic 5-HT; require 4–6 weeks for full antidepressant effect (downregulation of presynaptic 5-HT1A autoreceptors). Adverse effects: Sexual dysfunction (anorgasmia), GI upset, SIADH (hyponatremia in elderly), QT prolongation (citalopram), and serotonin syndrome. |
intermediate |
What are the mechanism of action, pain indications, and cardiovascular adverse effects of the SNRIs Venlafaxine, Desvenlafaxine, and Duloxetine? | Inhibit presynaptic reuptake of both serotonin and norepinephrine. Indicated for MDD, GAD, diabetic peripheral neuropathy, and fibromyalgia (duloxetine). Dose-dependent norepinephrine reuptake inhibition can cause sustained hypertension and diaphoresis; venlafaxine has a severe discontinuation syndrome due to its short half-life. |
intermediate |
How do Rapid-Acting (Lispro, Aspart), Short-Acting (Regular), Intermediate (NPH), and Long-Acting Basal (Glargine, Degludec) insulins compare in pharmacokinetic onset, peak, and duration? | Rapid-acting (Lispro, Aspart, Glulisine): onset 15 min, peak 1h, duration 3–4h (mealtime bolus). Short-acting (Regular): onset 30–60 min, peak 2–3h (only insulin given IV for DKA/hyperkalemia). Intermediate (NPH): peak 4–10h. Long-acting basal (Glargine, Degludec): peakless over 24+ hours. |
intermediate |
What are the mechanism of action, glycemic/weight benefits, and renal/iodinated contrast safety rules for Metformin (Glucophage)? | Biguanide that activates hepatic AMPK and inhibits mitochondrial complex I and glycerophosphate dehydrogenase, suppressing hepatic gluconeogenesis and improving peripheral insulin sensitivity without causing hypoglycemia or weight gain (chronic use can cause vitamin B12 deficiency). Contraindicated if eGFR < 30 mL/min/1.73 m² (do not initiate if eGFR 30–45); temporarily hold metformin at the time of or prior to iodinated IV contrast procedures if eGFR is 30–60 mL/min/1.73 m² (or with liver disease, alcoholism, acute heart failure, or intra-arterial contrast) and recheck eGFR at 48 hours before restarting to prevent Metformin-Associated Lactic Acidosis (MALA). |
advanced |
Albuterol (SABA) vs Salmeterol/Formoterol (LABA) — Beta-2 Agonist Mechanism & GINA Asthma Monotherapy Rule | Stimulate beta-2 adrenergic receptors (Gs -> adenylyl cyclase -> increased cAMP -> bronchial smooth muscle relaxation) and drive K+ into cells (causing hypokalemia and tremor). LABAs must NEVER be used as monotherapy in asthma without an inhaled corticosteroid (ICS) due to increased asthma-related mortality; GINA guidelines recommend ICS-formoterol as preferred reliever. |
advanced |
Ipratropium (SAMA) & Tiotropium/Umeclidinium (LAMA) — Mechanism & Role in COPD vs Asthma | Competitively block M3 muscarinic receptors on airway smooth muscle, preventing vagally mediated bronchoconstriction and mucus secretion. LAMAs are cornerstone maintenance therapy in COPD and severe asthma. Adverse effects: Dry mouth and acute urinary retention in men with BPH. |
advanced |
Volume of Distribution (Vd), Clearance (CL) & Elimination Half-Life (t1/2) — Core Pharmacokinetic Equations | Vd = Amount of drug in body / Plasma concentration (C0); Loading Dose = (Vd x Cp) / F. Maintenance Dose = (CL x Cp x tau) / F. Half-life t1/2 = (0.693 x Vd) / CL. It takes 4 to 5 half-lives for a drug infused at a constant rate to reach ~94–97% steady-state concentration (or be completely eliminated). |
advanced |
First-Order vs Zero-Order Elimination Kinetics — Classic Zero-Order Drugs ('PEA') | First-order kinetics: A constant FRACTION of drug is eliminated per unit time (rate is proportional to plasma concentration; t1/2 is constant). Zero-order (capacity-limited) kinetics: Enzymatic pathways are saturated, so a constant AMOUNT of drug is eliminated per unit time (concentration drops linearly; t1/2 increases as concentration rises). Classic zero-order drugs: Phenytoin, Ethanol, and Aspirin (at toxic doses). |
4. 8周间隔重复学习计划表
- 第 1–2 周:打牢基础(
basic): 完成基础阶段卡组(每天 30–32 张新卡)。重点训练核心定义与基础概念的快速识别,每天坚持 15–20 分钟完成到期复习队列。 - 第 3–5 周:核心应用(
intermediate): 在保持基础卡组每日间隔复习的同时,引入中级卡组(每天 20 张新卡)。翻卡前先口头或书面组织完整答案。 - 第 6–7 周:进阶精通与重难点突破(
advanced): 过渡到高级卡组(每天 15 张新卡)。采用穿插练习法(Interleaving)混合基础、中级与高级卡片,在模拟考场条件下强化辨析能力。 - 第 8 周:巩固冲刺与自测: 暂停学习新卡 7 天;清空 flashcards.world 上的所有待复习队列,并针对错满 2 次以上的顽固错卡进行专项重测。
5. 常见学习误区及规避方法
- 不经思考直接翻看答案:在翻转卡片之前,务必先在脑海中(或大声说出)组织好你的准确答案。
- 考前一晚突击死记 500 张卡:间隔重复依赖睡眠期间的记忆巩固。每天坚持 20–30 分钟远胜过周末一次 4 小时的突击。
- 忽略语境与解析:认真阅读每张卡片背面的完整例句或分析说明,理解概念在真实场景与考题中的运用。
- 跳过难度梯度:在进入
advanced高级卡组之前,先确保basic基础卡组的正确率达到 90% 以上。
6. 常见问题解答(FAQ)
学习 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 每天应该刷多少张闪卡?
为了实现可持续的长期记忆留存,建议每天学习 20 至 32 张新卡(1 个精选卡组)外加当日到期的复习队列(总计约 15–25 分钟)。
在 flashcards.world 上应该从哪个难度的 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 卡组开始?
建议先从基础阶段(basic)开始,检验对核心术语的掌握程度;当首轮正确率达到 85% 以上后,再进入中级阶段(intermediate)。
我可以在手机和电脑上同步学习 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 闪卡吗?
可以——本指南链接的所有卡组均可在 flashcards.world 上通过手机浏览器和电脑端直接免费学习。
在 flashcards.world 上浏览全部 临床最常处方 200 种核心药物(通用名、药理分类与作用机制) 闪卡卡组 →